The United Kingdom and the United States have established a landmark bilateral deal that will guarantee no duties on British drug exports being sold in the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to boost spending on drugs through the NHS. This pledge ensures that import taxes on these crucial products will be held at zero for a timeframe of three years.
This development comes after recent threats to significantly raise import taxes on patented pharmaceutical products, with increases mentioned reaching 100%.
"This deal with the United Kingdom strengthens the international landscape for new treatments and brings long-overdue fairness to American-British pharmaceutical trade," a statement said.
Commercial Importance
Drugs are one of the Britain's most significant export categories to the US, which is by far the biggest buyer for major companies like GSK and AstraZeneca.
Statistics show that in the year prior to September, the UK sold pharmaceutical products worth billions to the US. This figure represented 17.4% of British export trade in that timeframe.
"This deal secures jobs, boosts funding and facilitates the UK to emerge as a international leader for medical research," a minister remarked.
Specific NHS Changes
The deal involves several key commitments from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to increase total health service expenditure on drugs from 0.3% of GDP to 0.6% over the coming ten years.
- Payback Limit: The sum drug companies must refund to the NHS to stay within budget will be restricted at 15%. Previously, rebates were more than 20%.
Recent Tensions
The deal follows a ongoing dispute between the sector and the British authorities over medicine costs and approval rates.
The disagreement were exacerbated by assertions that US patients were paying several times more for the identical medicines than consumers in the UK and Europe.
Recently, several major manufacturing plans in the UK have been paused or scrapped, while multi-billion-dollar investments have been directed toward projects in the United States.
The Science Minister stated that the NHS must spend more on drugs, noting that its spending on drugs had shrunk as a percentage of its overall budget over the past decade.
